Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model

J Infect Dis. 2015 Jul 15;212(2):311-5. doi: 10.1093/infdis/jiv024. Epub 2015 Jan 16.


Antibodies against reduction modifiable protein (anti-Rmp Abs) can block complement-dependent killing of Neisseria gonorrhoeae by otherwise bactericidal Abs. An anti-lipooligosaccharide bactericidal monoclonal Ab (mAb) 2C7, a gonococcal vaccine candidate Ab, attenuates vaginal colonization by gonococci in BALB/c mice. Here we show that anti-Rmp Abs block the efficacy of mAb 2C7 in mice in a dose-dependent manner. Anti-Rmp Abs also counteract 2C7-mediated enhancement of C3 deposition on gonococci in vivo. The mouse model will prove useful to study how blocking Abs influence the efficacy of gonococcal vaccines. Preexisting anti-Rmp Abs will be an important consideration in evaluating the efficacy of gonococcal vaccine candidates.

Keywords: Neisseria gonorrhoeae; blocking antibody; vaccine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Bacterial / administration & dosage*
  • Antigens, Bacterial / immunology
  • Bacterial Load / immunology
  • Bacterial Outer Membrane Proteins / immunology*
  • Female
  • Gonorrhea / immunology*
  • Gonorrhea / microbiology
  • Gonorrhea / therapy
  • Humans
  • Immunization, Passive
  • Mice, Inbred BALB C
  • Neisseria gonorrhoeae / immunology*


  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Outer Membrane Proteins
  • Rmp protein, Neisseria